Alimera Sciences Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alimera Sciences Inc.
Having licensed rights to Movantik from AstraZeneca in February, RedHill has now offloaded EU rights to Cosmo. Calliditas to obtain PBC candidate in bid to acquire Genkyotex.
Keeping Track: Pfizer’s Talzenna Ensures Record Year For Novel US Approvals; Novartis Submits SMA Gene Therapy
The latest drug development news and highlights from our FDA Performance Tracker.
Yutiq, for posterior uveitis, will compete with two existing steroid products and should launch during the first quarter of 2019. EyePoint’s Dexycu, although approved in February, is still in scale-up and probably will launch a bit later.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
- Site Specific
- Drug Delivery
- Other Names / Subsidiaries
- Alimera Sciences Limited
- Alimera Sciences B.V